Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 309
Special Issue Editor
Special Issue Information
Dear Colleagues,
Cancer immunotherapy has emerged as a pioneering treatment modality that controls the host immune system to eradicate cancer cells. However, major challenges are still present, such as limited therapeutic benefits and off-target toxicities. As in conventional cancer therapy, recently, nanomedicines have been applied as a representative drug delivery platform for cancer immunotherapy to improve therapeutic efficacy and reduce side effects. For enhanced immunotherapy, nanomedicines can be utilized to remodel the tumor microenvironments, increase antigen presentation, and stimulate the immune cells. Of various nanomedicines, polymer-based nanomedicines hold great potential in biocompatibility, feasibility for chemical modifications, and versatility in combination with other organic/inorganic materials.
This Special Issue of Pharmaceutics aims to cover the advanced strategies exploiting Polymeric Nanomedicines for Cancer Immunotherapy.
Dr. Hyewon Ko
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biocompatible polymers
- cancer immunotherapy
- tumor microenvironment
- antigen presentation
- immune checkpoints
- combination therapy
- nanovaccines
